Breaking News, Financial News

Financial Report: Alexion 1Q

Soliris sales up 6%

Alexion

1Q Revenues: $600.3 million (+6%)

1Q Earnings: $91.3 million (-43%)

Comments: Sales of Soliris were $600.3 million, up 6%. The company entered three agreements in 1Q for the clinical development and commercialization of drug products and recorded R&D expense for upfront payments of $112.0 million. Restructuring expenses in the quarter related to the relocation of its European headquarters from Lausanne to Zurich, were $7.1 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters